LONDON (Alliance News) - GlaxoSmithKline PLC said Tuesday a Phase III study of patients with advanced renal cell carcinoma showed that 70% of patients preferred Glaxo's Votrient treatment to Sutent, which is owned by CP Pharmaceuticals International C.V.
CP Pharmaceuticals is comprised of Pfizer Manufacturing LLC and Pfizer Production LLC.
The study assessed 169 patients to assess their preference between the two drugs to continue treatment with. Glaxo said 70% of patients expressed a preference for Votrient, compared to 22% who preferred Sutent and 8% who had no preference.
Glaxo said the most commonly cited reasons for this preference were "better quality of life" and "less fatigue." Patients who preferred Sutent cited "less diarrhoea" and "better quality of life" most commonly.
The study did not measure or compare the clinical efficacy of either treatment.
Shares in Glaxo were trading down 0.6% at 1,581.89 pence Tuesday.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.